Academic and professional career

As well as providing medical and healthcare in daily clinical practice, I am passionate about other areas of my profession, like research (I participate in several working groups and clinical trials), teaching, and publication. The information below provides further details of my training and career.

Academic curriculum
Work
Research activity

Academic and professional career

I hold a cum laude doctorate from the University of Malaga and five different university qualifications (acute care in cardiology, cardiovascular prevention and cardiac rehabilitation, biomedical research in the healthcare context, expert in inherited cardiovascular diseases, and a master’s in heart failure). I have had articles published in the most prestigious specialist journals and I participate in both clinical trials and conferences. I lead the Atrial Fibrillation Working Group and am Secretary of the Andalusian Society of Cardiology. My medical practice focuses on caring for patients with acute and chronic cardiovascular disease. I am a member of the Heart Failure and Inherited Heart Conditions Unit and the Head of Admissions for the Area of Cardiology at Virgen de la Victoria University Hospital.

 

A) ACADEMIC QUALIFICATIONS

  • BACHELOR’S DEGREE IN MEDICINE AND SURGERY, Málaga University Medical Faculty (1994-2000)
    Second highest grades in my year.
  • DOCTORAL COURSE in Internal Medicine, Malaga University Medical Faculty Course of 2001-2003
  • PhD IN MEDICINE, Málaga University Medical Faculty. Reading and defence of Doctoral Thesis
    16 December 2008, resulting in the award of OUTSTANDING and CUM LAUDE.
  • DIPLOMA IN ADVANCED TRAINING IN LIFE SCIENCES RESEARCH
    (2007)
  • APPLIED MASTER’S postgraduate course in distance learning in acute care in
    Cardiology (01/12/2012-31/07/2014). Universidad Católica San Antonio.
  • APPLIED MASTER’S postgraduate course in cardiovascular prevention and cardiac rehabilitation (2016).
  • I MASTER IN BIOMEDICAL RESEARCH IN THE HEALTHCARE CONTEXT (2017-2018) University of Málaga
  • EXPERT CERTIFICATION IN INHERITED CARDIOVASCULAR DISEASES (2020-2021). Francisco de Vitoria University, Madrid. (2020-2021). Universidad Francisco de Vitoria de Madrid.
  • MASTER’S IN HEART FAILURE (2022-2023). Rey Juan Carlos University

B) PROFESSIONAL ACTIVITY

  • RESIDENCY IN CARDIOLOGY at Virgen de la Victoria University Hospital, Malaga (20/07/01-20/07/06)
  • Specialist in Cardiology, HOSPITAL PUNTA DE EUROPA (20/07/06-04/07/08)
  • Specialist in Cardiology, HOSPITAL COSTA DEL SOL PUBLIC COMPANY (20/07/08-26/07/19)
  • Specialist in Cardiology, VIRGEN DE LA VICTORIA UNIVERSITY HOSPITAL, MALAGA (since 27/07/19)
  • Cardiologist at HOSPITAL QUIRÓN MÁLAGA (April 2010 to October 2020)
  • Cardiologist at CENTRO MÉDICO FUENGIROLA (since April 2011)
  • Cardiologist at VITHAS XANIT INTERNACIONAL HOSPITAL (March 2020 to November 2022

C) RESEARCH–RELATED ACTIVITIES

  • PUBLICATIONS

-Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient setting. Piserra López-Fernández A, et al. Current problems in Cardiology. 2024;49(29).

-Adverse clinical outcomes and associated predictors in rivaroxaban-treated atrial fibrillation patients with renal impairment. Sánchez Caravaca JM, et al. The American Journal of Cardiology 2023;203:122-127.

-Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban. Marín F, et al. Journal of Comparative Effectiveness Research, 2023; 12(3).

-Analysis of the activity of the telephone nursing consultation on demand for patient with heart failure. Cruzado Alvarez C, et al. Enfermería clínica, 2023;33(2):137-140

-Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry. Esteve Pastor MA, et al. European Heart Journal Cardiovascular Pharmacotherapy 2022;9(1):38-46.

-Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions. Gómez Outes A, et al. Expert Opinion on Pharmacotherapy 2022;23(17):1941-1955.

-Una nueva mutación en el gen ACTA 1, posiblemente asociada con miocardiopatía dilatada sin miopatía concomitante. Díaz Expósito A, et al. Revista Española de Cardiología 2022;75(10): 851-853.

-Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018. Díaz Guzmán J, et al. Rev Esp Cardiol 2022;75(6).

-Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry. Perez Cabeza AI, et al. Eur J Clin Invest 2022;52(4):e13709

-Mejorar la prevención de la trombosis y las complicaciones cardiovasculares durante la pandemia de la COVID-19. Fernández Lozano I, et al. Rev Esp Cardiol 2021;21(A):1-8

-Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección en la era de la COVID-19. Masjuan Vallejo J, et al Rev Esp Cardiol 2021:21(A):9-17

-Impacto de los cambios en la prescripción del tratamiento anticoagulante en la incidencia de ictus. Freixa-Pamias R, Pérez Cabeza AI, Valle Muñoz A et al. Rev Esp Cardiol:21(A):18-22

-Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI. Pérez Cabeza et al. Nefrología. DOI: 10.1016/j.nefro.2020.04.016

-Recomendaciones de expertos en la mejora de la prevención efectiva del ictus isquémico en la fibrilación auricular no valvular. Papel de rivaroxaban. Pérez Cabeza et al. Rev. Esp Cardiol (aceptado publicación 2020).

-Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies. Anguita M et al. Drugs in context 2019;8:212606 DOI:10.7573/dic.212606

-Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Pérez Cabeza et al. Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):305-316. doi: 10.1016/j.rec.2018.03.009.

-TIMI-AF score and cardiovascular events in vitamin K antagonists (VKA)-naïve outpatients with atrial fibrillation. Pérez Cabeza, et al. Clin Cardiol 2018 Jul 30. doi: 10.1002/clc.23035. [Epub ahead of print]

-Perfil de pacientes con fibrilación auricular no valvular tratados con rivaroxabán en España: la desigualdad en el acceso a los anticoagulants orales directos (estudio HEROIC). Peris Vidal J et al. Cardiocore Junio 2018, in press. https://doi.org/10.1016/j.carcor.2018.04.002

-Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice. Pérez Cabeza et al. Future Cardiol 2018 May;14(3s):9-16. doi: 10.2217/fca-2018-0021

-Contemporary stroke prevention strategies in 11096 european patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Boriani G, et al. Europace 2017 Sep 14:doi:10.1093/europace/eux301.

-Discrepancias entre el empleo de las ecuaciones MDRD-4 IDMS y CKD-EPI, en vez de la ecuación Cockcroft Gault, en la determinación de la posologya de los anticoagulants orales directos en pacientes con fibrilación auricular. Pérez Cabeza AI, Chinchurreta Capote PA, et al. Ted Clin (Barc) 2017 Jul 21. pii: S0025-7753(17)30472-4. doi: 10.10-Obstrucción dinámica intraventricular izquierda inducida por esfuerzo. Cabrera Bueno F, Rodríguez Bailón I, López Salguero R, et al. Rev Esp Cardiol 2004;57(12):1179-87.

-Newly impaired glucose metabolism and prognosis after percutaneous revascularization. Jimenez-Navarro MF, Fernández-Pastor J, Garrido-Sánchez L, Molina-Mora MJ, Ortiz-García C, Alonso-Briales JH, Pérez-Cabeza A, Hernández-García JM, de Teresa-Galván E, Tinahones FJ. Cardiol J. 2014 Mar 27. Doi:10.5603/CJ.a2104.0024.

-Monitorización de la ablación del istmo cavotricuspídeo. Álvarez M, Pérez-Cabeza A, Carretero J. Cardiocore 2014, 39:71.

-Poor reproducibility of the oral glucose tolerance test in the diagnosis of diabetes during percutaneous coronary intervention. Jiménez Navarro MF, et al. Int J Cardiol. 2010 Jul 23;142(3):245-249.

-Tomografía computarizada con multidetectores de venas coronarias y terapia de resincronización. Yris Flores, A. Pérez Cabeza, Rubén Leta. Rev Esp Cardiol 2006; 59: 1070 – 1070.

-Disfunción ventricular sistólica, un nuevo marcador de enfermedad coronaria en pacientes con estenosis aórtica sin infarto de miocardio previo. Pérez Cabeza, Gómez Doblas, Morcillo Hidalgo, et al. Rev Esp Cardiol. 2005; 58 (2):218-21.16/j.medcli.2017.06.003

  • PARTICIPATION IN CLINICAL TRIALS/REGISTRIES

-Co-investigator in the CORONA clinical trial (rosuvastatin versus placebo in patients with heart failure and severe ventricular dysfunction

-Co-investigator in the STEEPLE clinicl trial (Intravenous low molecular weight heparin or unfractionated heparin sodium in percutaneous coronary catheterisation for patients undergoing coronary angioplasty and/or coronary stent implantation).

–MÁSCARA registry (prevalence of acute coronary syndrome in various Spanish hospitals).

–PREFER in AF registry (European Multi-nation Registry on the Prevention of Thromboembolic Events in Atrial Fibrillation).

–FANTASIIA registry (Atrial fibrillation: Influence of anticoagulation level and type on stroke and bleeding event incidence).

–EURObservational Research Programme. Long-term registry of patients with atrial fibrillation.

–GLORIA-AF 3: Global registry on long‐term oral antithrombotic treatment in patients with atrial fibrillation.

–ESTUDIO HEROIC: cross-sectional, observational study to assess the sociodemographic and clinical characteristics of patients treated with rivaroxaban in habitual clinical practice of haematologists, cardiologists and internists countrywide. Code: BAY-RIV-2014-01. Regional Coordinator for Eastern Andalusia.

-Non-interventional study on treatment with edoxaban in habitual clinical practice for patients with nonvalvular atrial fibrillation (ETNA-AF-Europe)

–EMIT AF/VTE:
Management of edoxaban in diagnostic and therapeutic procedures. Registry number: DSE-EDO-02-15

–ESTUDIO EMIR: An observational study to identify risk factors associated with
major cardiovascular events in patients with nonvalvular atrial fibrillation treated with a direct oral anticoagulant (rivaroxaban). Regional Coordinator for Eastern Andalusia.

-ENSAYO CLINICO AUGUSTUS (BMS CV185-316): Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.

–PACIFIC AF clinical trial (BAY 2433334 / 19765): Randomised, double-blind, phase 2 dose-finding multi-centre clinical trial with active treatment control, double dummy and parallel groups to compare the safety of the oral inhibitor FXIa BAY 2433334 with apixaban in patients with atrial fibrillation.

– OCEANIC AF clinical trial: A multi-centre, international, randomised, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm Phase III study investigating asundexian compared to apixaban in patients with atrial fibrillation at risk for stroke to determine the safety and efficacy of asundexian on prevention of stroke and systemic embolism

–LIBREXIA-AF clinical trial: A Phase 3, randomised, double-dummy, parallel group, active controlled study to evaluate the efficacy and safety of milvexian, an oral factor XIa Inhibitor, versus apixaban in participants with atrial fibrillation.

–EMPULSE clinical trial: A multi-centre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral empagliflozin 10 mg compared to a placebo, initiated in patients hospitalised for acute heart failure (de novo or decompensated chronic HF) who have been stabilised.

–FINEART HF clinical trial: A multi-centre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)

–DIAMOND clinical trial: Patiromer for the management of hyperkalemia in subjects receiving RAASi medications for the treatment of heart failure..

–HELIOS-B clinical trial: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

–PANDORA study: An observational ambidirectional study to analyse the evolutionary management of drugs with a prognostic effect on patients treated with the polypill as basic treatment on discharge after a first acute coronary syndrome.

  • PARTICIPATION AS CONFERENCE SPEAKER

I have participated in conferences as a speaker on over 50 occasions, mostly on subjects related
to the field of oral anticoagulants in atrial fibrillation.

D) TEACHING

I have undertaken different teaching responsibilities, foremost among which are:

–Tutor of cardiology residents at Virgen de la Victoria Hospital since 2022.

– Clinical practice tutor (Malaga University Medical Faculty) teacher/trainer in clinical practice 2013 to date.

-Author of training materials for postgraduate training course, Universitat Oberta de Catalunya.

-Lecturer, postgraduate expert course in ATRIAL FIBRILLATION (continuous postgraduate training). Author of the chapter: “Natural history and the possibilities of prevention”. University of Santiago de Compostela Spanish Society of Cardiology April-October 2014.

-Lecturer, courses in “Expert Management of Echocardiography” organised by IAVANTE, the Foundation for Technological Advance and Professional Training.

-Training activity educator, “Management of atrial fibrillation patients in the hospital healthcare environment”, organised by IAVANTE (2024).

-Coordinator of theory-practical courses in echocardiography given at Hospital de Alta Resolución, Benalmadena (2011.2012 and 2013).

-Lecturer, Master in Echocardiography, Universidad Católica de Murcia

E) OTHER ROLES

—Head of Admissions, Heart Area, Virgen de la Victoria University Hospital since October 2024.

–Secretary of the Andalusian Society of Cardiology (2024-2027)

-Member of the Spanish National Cardiology Commission since 2024.

–President of the Andalusian Society of Cardiology’s Atrial Fibrillation Working Group since May 2019.

-Chair of the SEC-Excelente-Proceso Atrial Fibrillation Working Group of the Andalusian Society of Cardiology since May 2019.

-Member of the CIBERCV Research Group led by Dr. Jiménez Nav

–Coordinator of the Healthcare Process for Atrial Fibrillation and Flutter of the Andalusian Regional Government’s Health Department

-Voting member of the Virgen de la Victoria University Hospital Multi-disciplinary Commission for the Rational Use of Medicines since 2024

-Voting member and Vice-president of the Costa del Sol Hospital Ethics Committee for Scientific Research (2013-2019).

-Member of the Costa del Sol Hospital Medical Records Commission (2012).

-Member of the Virgen de la Victoria Hospital Protocols Commission (2021.

–Coordinator of the Virgen de la Victoria Hospital Atrial Fibrillation process, certified in 2020 by Spanish Society of Cardiology’s SEC-Excelente project.

–Member of the Andalusian Society of Cardiology, the Spanish Society of Cardiology and the European Society of Cardiology.

Ask for a consultation

If you would like to contact me for a consultation, please send me a message. I’ll be in touch as soon as possible. I’ll be in touch as soon as possible.

Ask for a consultation